Evidence map›Paper›PMID 31359362›Full record

ArticleInternational journal of hematology2019

Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes.

Hiroshi Kawabata, Kensuke Usuki, Maki Shindo-Ueda, Junya Kanda, Kaoru Tohyama, Akira Matsuda, Kayano Araseki, Tomoko Hata, Takahiro Suzuki, Hidekazu Kayano and 11 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Hiroshi KawabataDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. hkawabat@kanazawa-med.ac.jp.ORCID http://orcid.org/0000-0002-1918-8635
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Maki Shindo-UedaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kaoru TohyamaDepartment of Laboratory Medicine, Kawasaki Medical School, Okayama, Japan.
Akira MatsudaDepartment of Hemato-Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.
Kayano ArasekiDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Saitama Medical University, Moroyama, Saitama, Japan.
Tomoko HataDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Takahiro SuzukiDepartment of Hematology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Hidekazu KayanoSchool of Medical Technology, Faculty of Health and Medical Care, Saitama Medical University, Hidaka, Saitama, Japan.
Kei ShimboClinical Laboratory Center, Dokkyo Medical University Hospital, Mibu, Tochigi, Japan.
Shigeru ChibaDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Takayuki IshikawaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Nobuyoshi ArimaDepartment of Hematology, Medical Research Institute Kitano Hospital, Osaka, Japan.
Masaharu NohgawaDepartment of Hematology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
Yasushi MiyazakiDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Mineo KurokawaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shunya AraiDepartment of Hematology, Tokyo Metropolitan Police Hospital, Tokyo, Japan.
Kinuko MitaniDepartment of Hematology and Oncology, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes

Funding

Ministry of Health, Labour and Welfare H20-Nanchi-Ippan-001Ministry of Health, Labour and Welfare H23-Nanchi-Ippan-001Ministry of Health, Labour and Welfare H26-Nanchi-Ippan-062Ministry of Health, Labour and Welfare H27-Nanchi-Ippan-016Ministry of Health, Labour and Welfare H29-Nanchi-Ippan-026
6 · The paper itself

Abstract

Serum ferritin, a marker of systemic iron status, is considered a prognostic factor for patients with myelodysplastic syndromes (MDS), despite the lack of supporting evidence. We investigated the association between serum ferritin levels at diagnosis and the prognoses of Japanese MDS patients with bone marrow blasts < 5% and peripheral blood blasts < 2%. Three hundred and ninety patients with cytopenia were registered prospectively in the multicenter database, among whom 107 patients with MDS (72 males and 35 females, with a median age of 70 years) met the eligibility criteria. The median serum ferritin level at diagnosis was 204 ng/mL; we divided the cohort into low (n = 56) and high (n = 51) ferritin groups using a cutoff of 210 ng/mL. Kaplan-Meier analyses revealed that the 3-year overall survival (OS) of the high ferritin group was significantly shorter than that of the low ferritin group (66% and 79%, respectively). The cumulative incidences of leukemic progression were similar between the groups. On multivariate analysis, age, blast percentage, cytogenetic abnormalities, and serum ferritin levels at diagnosis were independently associated with OS in our patients. Thus, modest elevations of ferritin levels at diagnosis may influence the prognoses of patients with MDS who have low blast counts.

Indexed as

AgedBlast CrisisDisease ProgressionFemaleFerritinsHumansJapanKaplan-Meier EstimateMaleMyelodysplastic SyndromesPrognosisProspective StudiesFerritinsFerritinIron overloadMyelodysplastic syndromesPrognosis

Identifiers

PMID31359362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.